Liminatus Pharma LIMN Income Statement (2024-2026)

NASDAQ LIMN
$0.11 +0.00 (+0.00%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter) 17.50M17.50M17.50M100.0026.01M27.06M27.06M36.00M
Operating items
Research & Development (Quarter) 0.71M0.36M0.40M
Selling, General & Administrative (Quarter) 0.20M0.19M0.17M0.26M1.12M0.70M0.88M0.70M
Operating Expenses (Quarter) 0.91M0.54M0.17M0.26M1.12M0.70M0.88M1.10M
Operating Income (Quarter) -0.91M-0.54M-0.17M-0.26M-1.12M-0.70M-0.88M-1.10M
EBIT (Quarter) -0.91M-0.54M-0.17M-0.26M-1.12M-0.70M-0.88M-1.10M
Non-operating items
Interest & Investment Income (Quarter) 0.03M0.03M0.04M0.05M0.02M
Non Operating Income (Quarter) -0.05M-0.06M-0.06M-0.06M1.23M-1.12M-7.28M-0.02M
Net income details
EBT (Quarter) -0.96M-0.60M-0.38M-0.33M-1.16M-0.72M-0.71M-1.12M
Profit After Tax (Quarter) -0.96M-0.60M-0.23M-0.33M0.11M-1.82M-8.17M-1.12M
Income from Continuing Operations (Quarter) -0.96M-0.60M-0.38M-0.33M-1.16M-0.72M-0.71M-1.12M
Consolidated Net Income (Quarter) -0.96M-0.60M-0.38M-0.33M-1.16M-0.72M-0.71M-1.12M
Income towards Parent Company (Quarter) -0.96M-0.60M-0.38M-0.33M-1.16M-0.72M-0.71M-1.12M
Net Income towards Common Stockholders (Quarter) -0.96M-0.60M-0.38M-0.33M0.11M-0.72M-0.71M-1.12M
Additional items
EPS (Basic) (Quarter) -0.05-0.03-0.02-0.00M0.00-0.03-0.03-0.03
EPS (Diluted) (Quarter) -0.05-0.03-0.02-0.00M0.00-0.03-0.03-0.03
Shares Outstanding (Quarter) 17.50M17.50M17.50M100.0023.30M27.01M23.75M36.00M
Shares Outstanding (Diluted) (Quarter) 17.50M17.50M17.50M100.0023.30M27.01M23.75M36.00M
EBITDA (Quarter) -0.91M-0.54M-0.17M-0.26M-1.12M-0.70M-0.88M-1.10M
Interest Expenses (Quarter) 0.08M0.09M0.26M0.12M0.06M0.02M-0.17M0.02M